bucillamine + etanercept + sulfasalazine

This is a combination therapy consisting of three disease-modifying antirheumatic drugs (DMARDs): bucillamine, etanercept, and sulfasalazine. - **Bucillamine** is a small molecule DMARD structurally related to D-penicillamine, primarily used in some countries for rheumatoid arthritis. It acts as an immunomodulator and antioxidant by modulating thiol-disulfide exchange reactions. - **Etanercept** is a biologic fusion protein that acts as a tumor necrosis factor (TNF) inhibitor by binding TNF-alpha and TNF-beta, preventing them from activating their receptors. - **Sulfasalazine** (also known as salazosulfapyridine) is an anti-inflammatory agent used in the treatment of rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis. It works by reducing inflammation through immunomodulatory effects; its mechanism involves breakdown into 5-aminosalicylic acid (mesalamine) and sulfapyridine in the colon[1][2][4]. The combination may be considered for patients with refractory or severe autoimmune conditions such as rheumatoid arthritis when monotherapy or dual therapy has proven insufficient.

Other names

bucillamine + etanercept + salazosulfapyridine